相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Review
Immunology
Paul Moss
Summary: T cell immunity plays a central role in controlling SARS-CoV-2 infection, with early responses correlating with protection. T cell memory provides broad recognition of viral proteins, limiting the impact of viral variants and offering protection against severe disease. Current COVID-19 vaccines elicit robust T cell responses, contributing to the prevention of hospitalization or death. Therefore, the importance of T cell immunity may have been underestimated.
Article
Biochemistry & Molecular Biology
Paul R. Wratil et al.
Summary: This study reports on the dynamics of neutralizing antibodies in individuals convalescing from coronavirus disease 2019 or who are vaccine-naive and subsequently vaccinated. The findings suggest that infection-plus-vaccination-induced hybrid immunity or triple immunization can induce high-quality antibodies with superior neutralization capacity against variants of concern, including omicron.
Article
Medicine, General & Internal
Victoria Hall et al.
Summary: This study investigated the duration and effectiveness of immunity among healthcare workers in the United Kingdom. It found that two doses of the BNT162b2 vaccine provided high short-term protection against SARS-CoV-2 infection, but this protection significantly decreased after six months. However, infection-acquired immunity boosted by vaccination remained high, even more than one year after infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Infectious Diseases
Rachel Hui Fen Lim et al.
Summary: This study reviewed the enhanced strategies implemented by a hospital in Singapore to prevent nosocomial transmission of COVID-19 amid the widespread community transmission of the Delta variant. The results showed that upgraded personal protective equipment (PPE) and rostered routine testing (RRT), staff sickness surveillance, and rigorous management of contacts of COVID-19 cases were effective in reducing nosocomial transmission.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Letter
Medicine, General & Internal
Michael Klompas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Editorial Material
Medicine, General & Internal
Salim S. Abdool Karim et al.
Article
Medicine, General & Internal
Alasdair P S Munro et al.
Article
Medicine, General & Internal
Noam Barda et al.
Summary: A study using data from Israel's largest health-care organization showed that a third dose of the BNT162b2 mRNA vaccine is effective in preventing individuals from severe COVID-19-related outcomes, compared to receiving only two doses at least 5 months ago. The effectiveness of the third dose in preventing hospital admission was 93%, severe disease 92%, and COVID-19-related death 81%.
Article
Multidisciplinary Sciences
Bruno Pozzetto et al.
Summary: The study found that a heterologous vaccination regimen using ChAdOx1-S-nCoV-19 and BNT162b2 can provide better protection against SARS-CoV-2 infection with stronger neutralizing activity. This approach can activate memory B cells that recognize SARS-CoV-2, making it suitable for immunocompromised individuals.
Article
Public, Environmental & Occupational Health
Thomas Theo Brehm et al.
Summary: The study assessed the presence of SARS-CoV-2 IgG antibodies in 1253 hospital workers at three time points during the early phase of the epidemic, with an overall seroprevalence of 1.8% by July 2020. This indicates the overall effectiveness of infection control interventions in mitigating COVID-19 among hospital workers.
INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH
(2021)
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Medicine, General & Internal
Alberto M. Borobia et al.
Summary: To date, there are no immunological data on COVID-19 heterologous vaccination schedules in humans. This study evaluated the immunogenicity and reactogenicity of administering BNT162b2 as a second dose in individuals primed with ChAdOx1-S. The results showed that BNT162b2 induced a robust immune response in individuals prime vaccinated with ChAdOx1-S, with an acceptable and manageable reactogenicity profile.
Article
Biochemistry & Molecular Biology
Joana Barros-Martins et al.
Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.
Article
Public, Environmental & Occupational Health
Thomas Theo Brehm et al.
Summary: This longitudinal cohort study found low SARSCoV-2 infection rates among hospital workers and high seroconversion rates after COVID-19 vaccination. Different vaccination strategies may impact antibody response levels.
INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH
(2021)
